These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
194 related articles for article (PubMed ID: 23330999)
1. Distinct IDH1/IDH2 mutation profiles in purely insular versus paralimbic WHO Grade II gliomas. Gozé C; Mansour L; Rigau V; Duffau H J Neurosurg; 2013 Apr; 118(4):866-72. PubMed ID: 23330999 [TBL] [Abstract][Full Text] [Related]
2. Subgroup characteristics of insular low-grade glioma based on clinical and molecular analysis of 42 cases. Tang C; Zhang ZY; Chen LC; Sun Z; Zhang Y; Qin Z; Yao Y; Zhou LF J Neurooncol; 2016 Feb; 126(3):499-507. PubMed ID: 26586262 [TBL] [Abstract][Full Text] [Related]
3. Molecular genetics of adult grade II gliomas: towards a comprehensive tumor classification system. Figarella-Branger D; Bouvier C; de Paula AM; Mokhtari K; Colin C; Loundou A; Chinot O; Metellus P J Neurooncol; 2012 Nov; 110(2):205-13. PubMed ID: 22890969 [TBL] [Abstract][Full Text] [Related]
4. Association Between IDH1 and IDH2 Mutations and Preoperative Seizures in Patients with Low-Grade Versus High-Grade Glioma: A Systematic Review and Meta-Analysis. Phan K; Ng W; Lu VM; McDonald KL; Fairhall J; Reddy R; Wilson P World Neurosurg; 2018 Mar; 111():e539-e545. PubMed ID: 29288860 [TBL] [Abstract][Full Text] [Related]
5. Non-canonical IDH1 and IDH2 mutations: a clonal and relevant event in an Italian cohort of gliomas classified according to the 2016 World Health Organization (WHO) criteria. Visani M; Acquaviva G; Marucci G; Paccapelo A; Mura A; Franceschi E; Grifoni D; Pession A; Tallini G; Brandes AA; de Biase D J Neurooncol; 2017 Nov; 135(2):245-254. PubMed ID: 28748342 [TBL] [Abstract][Full Text] [Related]
6. All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2. Labussière M; Idbaih A; Wang XW; Marie Y; Boisselier B; Falet C; Paris S; Laffaire J; Carpentier C; Crinière E; Ducray F; El Hallani S; Mokhtari K; Hoang-Xuan K; Delattre JY; Sanson M Neurology; 2010 Jun; 74(23):1886-90. PubMed ID: 20427748 [TBL] [Abstract][Full Text] [Related]
7. Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups. Weller M; Weber RG; Willscher E; Riehmer V; Hentschel B; Kreuz M; Felsberg J; Beyer U; Löffler-Wirth H; Kaulich K; Steinbach JP; Hartmann C; Gramatzki D; Schramm J; Westphal M; Schackert G; Simon M; Martens T; Boström J; Hagel C; Sabel M; Krex D; Tonn JC; Wick W; Noell S; Schlegel U; Radlwimmer B; Pietsch T; Loeffler M; von Deimling A; Binder H; Reifenberger G Acta Neuropathol; 2015 May; 129(5):679-93. PubMed ID: 25783747 [TBL] [Abstract][Full Text] [Related]
8. Clinico-neuropathological features of isocitrate dehydrogenase 2 gene mutations in lower-grade gliomas. Wang LM; Li Z; Piao YS; Cai YN; Zhang LY; Ge HJ; Xu WW; Lu DH Chin Med J (Engl); 2019 Dec; 132(24):2920-2926. PubMed ID: 31833906 [TBL] [Abstract][Full Text] [Related]
9. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Hartmann C; Meyer J; Balss J; Capper D; Mueller W; Christians A; Felsberg J; Wolter M; Mawrin C; Wick W; Weller M; Herold-Mende C; Unterberg A; Jeuken JW; Wesseling P; Reifenberger G; von Deimling A Acta Neuropathol; 2009 Oct; 118(4):469-74. PubMed ID: 19554337 [TBL] [Abstract][Full Text] [Related]
10. PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients. Draaisma K; Wijnenga MM; Weenink B; Gao Y; Smid M; Robe P; van den Bent MJ; French PJ Acta Neuropathol Commun; 2015 Dec; 3():88. PubMed ID: 26699864 [TBL] [Abstract][Full Text] [Related]
12. Whole-Tumor Histogram and Texture Analyses of DTI for Evaluation of Park YW; Han K; Ahn SS; Choi YS; Chang JH; Kim SH; Kang SG; Kim EH; Lee SK AJNR Am J Neuroradiol; 2018 Apr; 39(4):693-698. PubMed ID: 29519794 [TBL] [Abstract][Full Text] [Related]
13. Brain T1ρ mapping for grading and IDH1 gene mutation detection of gliomas: a preliminary study. Cao M; Ding W; Han X; Suo S; Sun Y; Wang Y; Qu J; Zhang X; Zhou Y J Neurooncol; 2019 Jan; 141(1):245-252. PubMed ID: 30414094 [TBL] [Abstract][Full Text] [Related]
14. Neuro-radiological characteristics of adult diffuse grade II and III insular gliomas classified according to WHO 2016. Compes P; Tabouret E; Etcheverry A; Colin C; Appay R; Cordier N; Mosser J; Chinot O; Delingette H; Girard N; Dufour H; Metellus P; Figarella-Branger D J Neurooncol; 2019 May; 142(3):511-520. PubMed ID: 30756272 [TBL] [Abstract][Full Text] [Related]
15. IDH1 and IDH2 mutations in postoperative diffuse glioma-associated epilepsy. Neal A; Kwan P; O'Brien TJ; Buckland ME; Gonzales M; Morokoff A Epilepsy Behav; 2018 Jan; 78():30-36. PubMed ID: 29172136 [TBL] [Abstract][Full Text] [Related]
16. Molecular investigation of isocitrate dehydrogenase gene (IDH) mutations in gliomas: first report of IDH2 mutations in Indian patients. Das BR; Tangri R; Ahmad F; Roy A; Patole K Asian Pac J Cancer Prev; 2013; 14(12):7261-4. PubMed ID: 24460285 [TBL] [Abstract][Full Text] [Related]
17. Conventional Magnetic Resonance Features for Predicting 1p19q Codeletion Status of World Health Organization Grade II and III Diffuse Gliomas. Peng X; Yishuang C; Kaizhou Z; Xiao L; Ma C J Comput Assist Tomogr; 2019; 43(2):269-276. PubMed ID: 30371623 [TBL] [Abstract][Full Text] [Related]
18. Combination genetic signature stratifies lower-grade gliomas better than histological grade. Chan AK; Yao Y; Zhang Z; Shi Z; Chen L; Chung NY; Liu JS; Li KK; Chan DT; Poon WS; Wang Y; Zhou L; Ng HK Oncotarget; 2015 Aug; 6(25):20885-901. PubMed ID: 26369702 [TBL] [Abstract][Full Text] [Related]